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tile form, some limitations have emerged in late onset patients 
treated with ERT. However it is worthy to hypothesize that com-
bination of two or more therapeutic strategies (ERT/induction 
of imuno tolerance, ERT/chaperone, ERT/SRT) could be more 
effective in GSDII patients.
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According to the Union Européenne des Médecines Spé-
cialistes (UEMS), Section of Physical and Rehabilitation Medi-
cine, rehabilitation is the medical specialty concerning with 
the promotion of physical and cognitive functioning, activities, 
participation and modifying personal and environmental fac-
tors (1). This definition is in accordance with the International 
Classification of Functioning, Disability and Health published 
in 2002 by the World Health Organization (2). Rehabilitation 
activities require a holistic approach through the preparation of 
an individual rehabilitation project and its implementation by 
one or more rehabilitative programs containing the immediate 
and intermediate objectives and the final functional outcome. To 
settle the individual rehabilitation project it is first important to 
define the functional limitations and social participation restric-
tions of the patient using specific assessment scales. The com-
prehensive assessment of the person affected by a metabolic 
myopathy should include the evaluation of the following items: 
a. trunk and upper and lower limbs ROM (Range of Motion); b. 
upper and lower limbs strength with the MMT (Manual Muscle 
es significantly reduced the number of hours/day in ventilation. 
In this cohort of patients cardiac hypertrophy was seen in 14% of 
juvenile-adult cases, this enhances the importance of regular car-
diac evaluation, even in adult patients. This large follow up study 
confirmed and extended the previous positive observations about 
efficacy and safety on late-onset GSDII patients (5).
Side effects of rhGAA
In all the above mentioned studies adverse events in pa-
tients on ERT were mild to moderate and infusion-related or 
during the first 2 hours post-infusion. No ERT related death 
occurred.  Immunological  responses  were  seen  in  the  major-
ity of the patients, who developed anti-rhGAA IgG antibodies 
within the first 3 months of ERT that limited the treatment ef-
ficiacy (4, 5).
Experimental therapies
Different therapeutic approaches are ongoing as alternative 
or associated treatment to ERT.
In particular, gene therapy for Pompe disease has been ex-
plored by several groups. The feasibility of this approach was 
firstly shown in vitro studies using retroviral and adenoviral 
vectors expressing human GAA. In order to improve the effi-
cacy of the viral vectors and minimize the immune response, 
several approaches have been tried : modification of the GAA 
cDNA sequence, different promoters, and different AAV sero-
types (6).
Enzyme enhancement therapy (EET) is based on the ability 
of pharmacological chaperones/active site inhibitors to rescue 
mis-folded or unstable proteins from ER-associated degradation 
by increasing the amount of protein that passes the cell’s qual-
ity control system. Various inhibitors and derivatives of deox-
ynojirimycin (DNJ) have been tested in other lysosomal storage 
diseases. A number of missense mutations found in late-onset 
Pompe patients result in retention and premature degradation of 
the GAA precursor in the ER. These mutations may be amena-
ble to chaperone-mediated therapy (7).
Another  treatment  approach  under  observation  is  based 
on the enhanced delivery of the therapeutic enzyme. Currently 
available preparations of rhGAA contains a relatively low num-
ber of M6P residues. In order to improve the delivery of the 
therapeutic enzyme and to facilitate a reduction of the drug dos-
age, a second generation of the rhGAA (neo-rhGAA) with a 
higher affinity for the CI-MPR was made. This process involves 
a chemical conjugation to rhGAA of an oligosaccharide ligand 
bearing M6P residues in the optimal configuration (8).
A recent therapeutic have emerged as a possibile relevant 
option  to  be  combined  with  ERT,  called  substrate  reduction 
therapy (SRT). It aims to decrease of the amount of glycogen, 
modulating glycogen synthesis. Glycogen synthesis (GYS) can 
be modulated by mTOR which is the mammalian target of ra-
pamacin. A GAA-KO mice treated with rapamacin, exhibited a 
significant decrease of muscular glycogen due to the phosphor-
ylation-mediated inhibition of GYS1 (8).
Conclusions
So  far,  ERT  is  the  only  approved  treatment  for  Pompe 
disease. Whereas  impressive  results  were  obtained  in  infan-208
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The progressive muscular damage in patients affected by 
Glycogenosis  type  II  can  be  slowed  down  through  lifestyle 
changes based on a specific dietotherapy and daily physical ex-
ercise. Dietary treatment provides for a diet made up of pro-
teins (25-30%), carbohydrates (30-35%), fat (35-40%), that is a 
high-protein diet for the most part. Patients suffering such the-
saurismosis need a higher amount of proteins since the increase 
in amino acids, which function as substrate for the synthesis of 
proteins, could make up for the proteolysis of muscular tissue. 
Proteins coming from meat, fish, egg, and dairy products are to 
be preferred; such food, moreover, is rich in alanine, an amino 
acid playing a key role in glycide metabolism and, consequently, 
in the employment of glucose as a source of energy. So much 
so that a further oral supplement is recommended, in a dose of 
0,4g/kg divided 3-4 times per day. Lipids are recommended in 
the form of unsaturated fats (omega-3, which are mainly con-
tained in bluefish) and saturated fats (omega-6, which are main-
ly contained in olive oil, dried fruit and cereals), reducing to 
a minimum saturated ones due to their aterogenic effect. The 
assumption of carbohydrates must not only be reduced to 30-
35%, but also distributed in the space of a day. The “a little and 
often” rational consists in avoiding the build-up of glycogen on 
the one hand, and hypoglycaemia on the other. Among complex 
carbohydrates wholemeal ones such as cereals, legumes, and 
wholemeal pasta are to be preferred, in small helpings; whereas, 
among simple ones, dried or skinned (if fresh) fruit; such recom-
mendation aims at increasing the input of fibres in order to coun-
ter constipation, which is often found in those patients. Muscular 
pain, in fact, can also concern the gastrointestinal system, with 
consequent  dysphagia,  gastroesophageal  reflux,  gastroparesis 
and a reduction in appetite. Such conditions are treated with die-
tary and pharmacological measures to avoid malnutrition. In the 
team in charge of treatment, the presence of a physiotherapist is 
essential to carry out exercises in coordination and contraction 
of facial muscles, postural training and rehabilitation to tasting. 
Anthropometric data and bodily composition represent param-
Testing); c. pain with several scales such as VAS (Visual Ana-
logic Scale), Pediatric Pain Objective scale, and BPI (Brief Pain 
Inventory) (3) global functioning with the Six Minute Walk (4) 
and the Gross Motor Function Measure (GMFM) (5) disability 
with the Pediatric Evaluation of Disability Index (PEDI), (6) the 
Pompe PEDI,(7) the Functional Independent Measure (FIM), 
(8) the WeeFIM, (9) the Barthel Index (10) and the ADL (11)/
IADL(12); quality of life with the Rotterdam Handicap Scale 
(RHS) (13) and the Short Form 12 (SF-12)(14). In particular, 
in patients with Pompe disease we have to deal with a deep, 
progressive and symmetrical muscle weakness, proximal more 
than distal, involving the lower extremities more frequently than 
the upper ones, that will determine contractures and deformi-
ties. Moreover there are often neck and trunk muscle weakness 
involving respiratory muscles (diaphragm, intercostals, abdomi-
nal and accessory muscles) and this might lead to respiratory 
failure. Facial and oralmotor weakness is responsible not only 
of problems of mastication and phonation, but can also give the 
typical myopathic facies. In terms of functional limitations, my-
opathic patients experience deficit of walking ability resulting in 
the need of orthoses or wheelchair, loss of personal autonomy in 
the activities of daily living, relational-communicative, mental 
and emotional disabilities. The rehabilitation management of 
Pompe disease should be comprehensive and preventive, based 
on an understanding of the pathogenesis of disease progression 
and on individual assessment. The key of management lies in 
considering the interaction between the presence, progression 
and potential remediation of weakness and fatigue. It should op-
timize and preserve motor and physiological function, prevent 
or minimize secondary complications, promote and maintain the 
maximum level of functional independence and participation, 
and improve the quality of life; maximize the benefits of therapy 
recombinant and other therapies when they become available.
The  rehabilitative  approach  is  nowadays  mandatory  for 
comprehensive management of patients affected by metabolic 
myopathies.
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